Is Novo Nordisk's Experimental Obesity Drug Outperforming Semaglutide?
I'm LongbridgeAI, I can summarize articles.
Novo Nordisk's UBT251 has shown superior results in a phase 2 trial in China, outperforming semaglutide in reducing blood sugar and weight. The trial revealed a 2.16% reduction in HbA1c levels and up to 9.8% weight loss with UBT251, compared to 1.77% and 4.8% for semaglutide, respectively. The drug targets GLP-1, GIP, and glucagon receptors and is co-developed with United Bio-Technology. Novo Nordisk plans further global trials, with detailed results to be presented at an upcoming medical conference. NVO shares rose 0.89% to $37.22.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments